Sarepta Therapeutics (SRPT) Receivables - Other (2011 - 2026)

Sarepta Therapeutics' Receivables - Other history runs 16 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 147.1% year-over-year to $136.4 million in Q1 2026; TTM through Mar 2026 was $136.4 million, a 147.1% increase from a year earlier, with the FY2025 full-year figure at $104.1 million, up 200.87% from the prior year.
• Receivables - Other advanced to $136.4 million in Q1 2026 per SRPT's latest filing, from $104.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $136.4 million in Q1 2026 and bottomed at $17.7 million in Q1 2022.
• The 5-year median for Receivables - Other is $35.4 million (2023), against an average of $53.7 million.
• Across the five-year window, Receivables - Other jumped 522400.0% in 2022 and tumbled 51.45% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $41.8 million in 2022, then declined by 28.71% to $29.8 million in 2023, then gained by 16.11% to $34.6 million in 2024, then jumped by 200.87% to $104.1 million in 2025, then surged by 31.03% to $136.4 million in 2026.
• Per Business Quant, the three latest SRPT Receivables - Other figures stand at $136.4 million (Q1 2026), $104.1 million (Q4 2025), and $128.7 million (Q3 2025).